| | | | |
CUSIP No. 71722W107 | | Schedule 13G | | Page 2 of 4 |
ITEM 1. | (a) Name of Issuer: |
Phathom Pharmaceuticals, Inc. (the “Issuer”)
| (b) | Address of Issuer’s Principal Executive Offices: |
100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.
ITEM 2. | (a) Name of Person Filing: |
This statement is filed on behalf of Tadataka Yamada (the “Reporting Person”).
| (b) | Address or Principal Business Office: |
The business address of the Reporting Person is c/o Phathom Pharmaceuticals, Inc., 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.
| (c) | Citizenship of each Reporting Person is: |
The Reporting Person is a citizen of the United States.
| (d) | Title of Class of Securities: |
Common Stock, $0.0001 par value per share (“Common Stock”).
71722W107
Not applicable.
(a) Amount beneficially owned:
This amendment to Schedule 13G is being filed on behalf of the Reporting Person to report that, as of December 31, 2021, the Reporting Person does not beneficially own any shares of Common Stock.